Palatin Technologies Reports Q1 2027 Financial Results and Obesity Program Milestones
Palatin Technologies (PTN) reported its fiscal first quarter results for the period ending September 30, 2026. The company recorded revenue of $362,000 from research services under its collaboration with Boehringer Ingelheim, a significant decrease from the prior year's $8.8 million which included milestone payments. Net loss for the quarter was $5.1 million, or $1.29 per share, driven by increased R&D spending of $3.4 million. The company is heavily focused on its MC4R obesity program, with $2.1 million spent to advance IND-enabling studies. Management has set a target to initiate Phase I clinical trials for its lead lipidated peptide candidate in the first half of 2027. However, CFO Steve Wills cautioned that current cash reserves of $3.7 million may be insufficient to fund upcoming clinical development stages, necessitating potential future financing.